Events & Presentations Corporate Presentation Date Documents January 13, 2025 Corporate Presentation - January 2025 Upcoming Events There are currently no events to display. Archived Investor Events and Presentations Archived Scientific Presentations There are currently no events to display. Date Documents December 9, 2024 ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy October 10, 2024 UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease March 6, 2024 Vudalimab (PD-1 x CTLA-4) Monotherapy in mCRPC - Clinical Update with Additional Data November 3, 2023 SITC 2023: A phase 1, first-in-human, open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors April 17, 2023 AACR 2023: Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors December 12, 2022 ASH 2022: A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis November 10, 2022 A Phase 2 Study of Vudalimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer November 10, 2022 A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Patients With Relapsed or Refractory Clear Cell Renal Cell Carcinoma November 10, 2022 A Phase 2 Study of Vudalimab, a PD-1 × CTLA-4 Bispecific Antibody, Plus Chemotherapy or Targeted Therapy in Patients With Molecularly Defined Subtypes of Metastatic Castration-Resistant Prostate Cancer December 12, 2021 Phase 1 Safety and Anti-tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma November 12, 2021 SITC 2021: Preliminary Clinical Experience With Vudalimab, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors April 10, 2021 Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells November 9, 2020 Preliminary Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of XmAb®20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors November 9, 2020 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors June 22, 2020 AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies December 9, 2019 ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL March 4, 2019 Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format November 9, 2018 SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation April 16, 2018 AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation November 13, 2017 SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T CellActivation and Proliferation April 4, 2017 AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation November 9, 2016 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation November 9, 2016 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation December 7, 2014 American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111
